...
首页> 外文期刊>International Journal of Pharmaceutics >The influence of surface active L-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders
【24h】

The influence of surface active L-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders

机译:表面活性L-亮氨酸和1,2-Dipalmitoyl-Sn-甘油 - 3-磷脂酰胆碱(DPPC)在改善吡嗪酰胺和Moxifloxacin共吸干粉末的改善中的影响

获取原文
获取原文并翻译 | 示例

摘要

Pharmacotherapy of tuberculosis is potentially more efficient when delivered by the inhaled route than by the current oral and/or parenteral routes due to the higher concentration of drug reaching the primary region of infection in the lungs. This study investigated the influence of the amino acid L-leucine alone and in combination with the phospholipid, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), on the aerosolization behaviour of the anti-TB drugs, pyrazinamide and moxifloxacin HCl. Spray dried powders of pyrazinamide (P), moxifloxacin (M) alone and in combination with 10% L-leucine (PL and ML) and 10% DPPC (PLD and MLD) were produced. The particle sizes of all powders except P were in the inhalable size range ( 5 mu m) but differ in their morphology in presence of the excipients. X-ray photoelectron spectroscopy (XPS) and time-of-flight secondary ion mass spectrometry (ToF-SIMS) revealed the migration of surface active L-leucine and DPPC onto the surface of the particles during the spray drying process. The aerosolization from a dry powder inhaler, Aerolizer (R), using a Next Generation Impactor revealed fine particle fraction (FPF) values for P, PL and PLD of 18.7 +/- 3.4%, 53.0 +/- 3.2% and 74.5 +/- 5.3% respectively while FPF values for M, ML and MLD were 55.6 +/- 3.3%, 74.7 +/- 4.7% and 74.1 +/- 1.3% respectively. In conclusion, the differences in the aerosolization behaviours of the pyrazinamide and moxifloxacin spray dried powders with and without excipients was a combination of difference in the surface morphology and surface composition.
机译:当由于吸入的途径而不是当前口腔和/或肠胃外途径而导致的药物和/或肠胃外途径的药物疗法可能更有效,这是由于肺部中的药物较高的药物浓度较高。本研究研究了单独的氨基酸L-亮氨酸的影响,并与磷脂,1,2-Dipalmitoyl-Sn-甘油-3-磷脂酰胆碱(DPPC)组合在抗TB药物,吡嗪酰胺和吡嗪酰胺的雾化行为上Moxifloxacin HCl。单独使用吡嗪酰胺(P),莫西沙星(M)的喷雾干燥粉末,并与10%L-亮氨酸(PL和ML)和10%DPPC(PLD和MLD组合。除了P的所有粉末的粒径位于可吸入尺寸范围(&5μm)中,但在赋形剂存在下的形态不同。 X射线光电子能谱(XPS)和飞行时间二次离子质谱(TOF-SIMS)显示出在喷雾干燥过程中表面活性L-亮氨酸和DPPC迁移到颗粒表面上。干粉吸入器,空气化器(R),采用下一代撞击器,采用下一代撞击器显示出PL和PLD为18.7 +/- 3.4%,53.0 +/- 3.2%和74.5 + /的细粒级分(FPF)值。 - 分别为5.3%,而M,Ml和MLD的FPF值分别为55.6 +/- 3.3%,74.7 +/- 4.7%和74.1 +/- 1.3%。总之,吡唑胺和莫西沙星喷雾干燥粉末的雾化行为的差异在没有赋形剂中是表面形态和表面组合物的​​差异的组合。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号